Announcement from the Nomination Committee concerning the Annual General Meeting 2019

The Nomination Committee has consisted of Axel Calissendorff, Chairman of the nomination committee (appointed by Flerie Participation AB), Lars Backsell (Chairman of Recipharm), Johan Lannebo (appointed by Lannebo Fonder AB) and Ossian Ekdahl (appointed by Första AP-Fonden).

Wenche Rolfsen has declined re-election.

The Nomination Committee proposes re-election of Marianne Dicander Alexandersson, Lars Backsell, Carlos von Bonhorst, Anders G. Carlberg, Thomas Eldered and Helena Levander and election of Ashwini Kakkar and Eva Sjökvist Saers.

Further, Lars Backsell is proposed to be re-elected as Chairman of the Board of Directors.

The Nomination Committee’s other proposals, for example regarding Chairman of the Annual General Meeting, fees for the board and auditor and election of auditor, will be available on the website and published in the notice to attend the Annual General Meeting.

The Annual General Meeting of Recipharm will be held on 13 May 2019 at 3.00 pm at IVA’s premises at Grev Turegatan 16 in Stockholm.

Contact information
Axel Calissendorff, Chairman of the Nomination Committee, telephone: +46 768 40 91 03
or
Lars Backsell, Chairman of the Board of Directors and member of the Nomination Committee, telephone: +46 8 602 52 00 

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 6.4 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com 

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00

www.recipharm.com

Tags:

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 6.4 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com